Obefazimod (ABX464)
Ulcerative Colitis
About Abivax
Abivax is a clinical-stage biotech focused on developing first-in-class oral therapies that modulate the immune system via microRNA-124 enhancement. Its lead asset, obefazimod, has demonstrated positive Phase 3 induction results in ulcerative colitis, positioning it as a potential novel therapeutic with a unique mechanism. The company's strategy leverages its proprietary platform to expand into other inflammatory indications like Crohn's disease while exploring follow-on compounds from its chemical library. With a public listing on Euronext Paris and a valuation over $8B, Abivax is approaching key clinical and regulatory milestones that could validate its platform and drive future growth.
View full company profileAbout Abivax
Abivax is a clinical-stage biotech focused on developing first-in-class oral therapies that modulate the immune system via microRNA-124 enhancement. Its lead asset, obefazimod, has demonstrated positive Phase 3 induction results in ulcerative colitis, positioning it as a potential novel therapeutic with a unique mechanism. The company's strategy leverages its proprietary platform to expand into other inflammatory indications like Crohn's disease while exploring follow-on compounds from its chemical library. With a public listing on Euronext Paris and a valuation over $8B, Abivax is approaching key clinical and regulatory milestones that could validate its platform and drive future growth.
View full company profileAbout Abivax
Abivax is a clinical-stage biotech focused on developing first-in-class oral therapies that modulate the immune system via microRNA-124 enhancement. Its lead asset, obefazimod, has demonstrated positive Phase 3 induction results in ulcerative colitis, positioning it as a potential novel therapeutic with a unique mechanism. The company's strategy leverages its proprietary platform to expand into other inflammatory indications like Crohn's disease while exploring follow-on compounds from its chemical library. With a public listing on Euronext Paris and a valuation over $8B, Abivax is approaching key clinical and regulatory milestones that could validate its platform and drive future growth.
View full company profileOther Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |